✦ LIBER ✦

Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines

✍ Scribed by Poprach, Alexandr; Pavlik, Tomas; Melichar, Bohuslav; Kubackova, Katerina; Bortlicek, Zbynek; Svoboda, Marek; Lakomy, Radek; Vyzula, Rostislav; Kiss, Igor; Dusek, Ladislav; Buchler, Tomas

Book ID: 122144415
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 198 KB
Volume: 32
Category: Article
ISSN: 1078-1439
DOI: 10.1016/j.urolonc.2013.09.011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cardiac Toxicity of Sunitinib and Sorafe

Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma

✍ Kibel, A.S. 📂 Article 📅 2009 🏛 Elsevier Science ⚖ 38 KB

Prognostic nomogram for sunitinib in pat

Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma

✍ Robert J. Motzer; Ronald M. Bukowski; Robert A. Figlin; Thomas E. Hutson; M. Dro 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 3 views

## Abstract ## BACKGROUND. In a randomized, phase 3 trial, sunitinib demonstrated superior efficacy over interferon‐alfa as first‐line therapy in patients with metastatic clear‐cell renal cell carcinoma (RCC). On the basis of outcome data from that trial, the authors developed a nomogram for predi

Clinical efficacy and prognostic factors

Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib

✍ Takeshi Yuasa; Norihiko Tsuchiya; Shinji Urakami; Yohei Horikawa; Shintaro Narit 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 346 KB

Clinical Outcomes for Patients with Meta

Clinical Outcomes for Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules

✍ Atkinson, Bradley J.; Kalra, Sarathi; Wang, Xuemei; Bathala, Tharakeswara; Corn, 📂 Article 📅 2014 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 569 KB

Objective response and time to progressi

Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma

✍ Tomas Buchler, Tomas Pavlik, Zbynek Bortlicek, Alexandr Poprach, Rostislav Vyzul 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 176 KB

Third-line sunitinib following sequentia

Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma

✍ Hideaki Miyake,Yuji Kusuda,Ken-ichi Harada… 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 230 KB